EUCTR2006-001404-37-NL进行中（未招募）1 期
Cardiometabolic risk reduction by Rimonabant: the effectiveness in daily practice and its use - CARDIO-REDUSE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •we aim to include males and females 18 – 70 years of age who have a waist circumference >88 cm in women or >102 cm in men and diabetes mellitus type 2 or an impaired fasting blood glucose > 6.1 mmol/l in venous plasma.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USEISRCTN63367873niversity Maastricht (UM) (The Netherlands)600
招募中
不适用
CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE.NL-OMON20796Maastricht University600
终止
3 期
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and OutcomesCardiovascular DiseaseNCT00263042Sanofi18,695
终止
2 期
The Effects of Rimonabant, on Weight and Metabolic Risk FactorsSmokingHypertensionSchizoaffective DisorderSchizophreniaObesityNCT00547118University of Maryland, Baltimore17
进行中（未招募）
1 期
The Rimonabant in treatment of Prediabetes Study: a randomised clinical trial of Rimonabant in the treatment of patients with Prediabetes - Rimonabant StudyImpaired Glucose tolerance and Impaired fasting Glycaemia (Together known as Prediabetes)MedDRA version: 9.1 Level: LLT Classification code 10000146 Term: Abnormal glucose tolerance test (excl DM)MedDRA version: 9.1 Level: LLT Classification code 10056997 Term: Impaired fasting glucoseEUCTR2007-000940-28-GBniversity Hospitals of Leicester NHS Trust300